Schnitzer TJ, et al. - In this randomized, double-blind, multicenter trial involving 698 patients, researchers analyzed the impact of subcutaneous tanezumab on joint pain, physical function, and patient global assessment of osteoarthritis (PGA-OA). For this investigation, study participants received by subcutaneous administration either tanezumab, 2.5 mg, at day 1 and week 8 (n = 231); tanezumab, 2.5 mg at day 1 and 5 mg at week 8 (ie, tanezumab, 2.5/5 mg; n = 233); or placebo at day 1 and week 8 (n = 232). Among patients with moderate to severe knee or hip OA and inadequate response to standard analgesics, tanezumab compared to placebo resulted in statistically significant improvements in pain and physical function scores, and in PGA-OA, although the improvements were modest and patients treated with tanezumab experienced more joint safety events and total joint replacements.